Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merus raises €31m as J&J third corporate VC to invest

This article was originally published in Scrip

Executive Summary

Merus of the Netherlands has added to its series B round with a further €31m, bringing the total round to €47.6m. Johnson & Johnson Development Corporation (JJDC) joined as a new investor, and existing investors Novartis Venture Fund, Pfizer Venture Investments, Bay City Capital, LSP (Life Sciences Partners) and Aglaia Oncology Fund also participated.

Advertisement

Related Content

Broad-Based Incyte/Merus Collaboration Includes Up To 11 Bispecific Antibody Programs

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC022983

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel